Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in . gov or . mil. Before sharing sensitive information, make sure you’re on a federal government site VSports app下载. .

Https

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. V体育官网.

Clinical Trial
. 2011 Jan 20;117(3):1061-70.
doi: 10.1182/blood-2010-07-293795. Epub 2010 Oct 15.

Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics

Claudio G Brunstein  1 , Jeffrey S Miller, Qing Cao, David H McKenna, Keli L Hippen, Julie Curtsinger, Todd Defor, Bruce L Levine, Carl H June, Pablo Rubinstein, Philip B McGlave, Bruce R Blazar, John E Wagner
Affiliations
Clinical Trial

Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics

VSports app下载 - Claudio G Brunstein et al. Blood. .

Abstract

Acute graft-versus-host disease (aGVHD) is associated with high risk of morbidity and mortality and is a common complication after double umbilical cord blood (UCB) transplantation. To reduce these risks, we established a method of CD4(+)CD25(+)FoxP3(+) T regulatory cell (Treg) enrichment from cryopreserved UCB followed by a 18 (+) 1-day expansion culture including anti-CD3/anti-CD28 antibody-coated beads and recombinant human interleukin-2. In a "first-in-human" clinical trial, we evaluated the safety profile of UCB Treg in 23 patients VSports手机版. Patients received a dose of 0. 1-30 × 10(5)UCB Treg/kg after double UCB transplantation. The targeted Treg dose was achieved in 74% of cultures, with all products being suppressive in vitro (median 86% suppression at a 1:4 ratio). No infusional toxicities were observed. After infusion, UCB Treg could be detected for 14 days, with the greatest proportion of circulating CD4(+)CD127(-)FoxP3(+) cells observed on day (+)2. Compared with identically treated 108 historical controls without Treg, there was a reduced incidence of grade II-IV aGVHD (43% vs 61%, P = . 05) with no deleterious effect on risks of infection, relapse, or early mortality. These results set the stage for a definitive study of UCB Treg to determine its potency in preventing allogeneic aGVHD. This study is registered at http://www. clinicaltrials. gov as NCT00602693. .

PubMed Disclaimer

Figures

Figure 1
Figure 1
Box-plots show the kinetics of CD127-Foxp3+ cells. Proportions and absolute numbers of peripheral blood Treg were determined before and after the infusion of fresh culture-expanded UCB Tregs that were administered 1 day after UCB transplantation (all patients) and again, before and after the infusion of thawed UCB Treg (same donor) 15 days after UCB transplantation (11/17 recipients of CsA/MMF and 6/6 recipients of sirolimus/MMF). In the plot, the cross represents the median value, the box represents the interquartile range, and the vertical line represents the range of the results. Panels A and B show the proportion and absolute number per microliter of peripheral blood CD127-Foxp3+ cells within the CD4+ subset, specifically in recipients of CsA/MMF. Panels C and D show the proportion and absolute number per microliter of peripheral blood CD127-Foxp3+ cells within the CD4+ subset, specifically in recipients of sirolimus/MMF. In a subgroup of 7 patients who had informative HLA discrepancies and received infusions on day +1 and +15 that could be studied by flow cytometry depicting the proportion (E) and absolute numbers per microliter (F) of peripheral blood CD4+CD127−Foxp3+ cells derived from the regulatory T-cell donor unit. (*) In panel B, at the pretransplantation time point the figure excludes one outlier with an absolute Treg count of 152/μL.
Figure 2
Figure 2
Clinical outcomes of patients after nonmyeloablative umbilical cord blood transplantation who received Treg ≥ 30 × 105/kg (dotted line; n = 18) and historical controls (solid line; n = 108). (A) DFS (P = .25), (B) NRM (P = .51), (C) sustained donor engraftment (P = .89), and (D) grade II-IV aGVHD (P = .04).
See this image and copyright information in PMC

Comment in

  • Can Treg therapy prevent GVHD?
    Komanduri KV, Champlin RE. Komanduri KV, et al. Blood. 2011 Jan 20;117(3):751-2. doi: 10.1182/blood-2010-11-317305. Blood. 2011. PMID: 21252098 No abstract available.

References

    1. Godfrey WR, Spoden DJ, Ge YG, et al. Cord blood CD4(+)CD25(+)-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function. Blood. 2005;105(2):750–758. - V体育官网 - PubMed
    1. Randolph DA, Fathman CG. Cd4+Cd25+ regulatory T cells and their therapeutic potential. Annu Rev Med. 2006;57:381–402. - PubMed (V体育2025版)
    1. Cohen JL, Trenado A, Vasey D, Klatzmann D, Salomon BL. CD4(+)CD25(+) immunoregulatory T cells: new therapeutics for graft-versus-host disease. J Exp Med. 2002;196(3):401–406. - PMC - PubMed
    1. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med. 2002;196(3):389–399. - PMC - PubMed
    1. Taylor PA, Noelle RJ, Blazar BR. CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. J Exp Med. 2001;193(11):1311–1318. - PMC - PubMed

Publication types

MeSH terms

"VSports" Associated data